CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.

Inclusion Criteria: * Life expectancy ≥ 3 months * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Adequate organ function and hematologic reserve based on laboratory parameters * Have measurable disease defined by RECIST v1.1 * Willingness to provide recent archival tumor tissue sample or willingness to undergo biopsy * Tumor indication specific inclusion criteria: * Is progressing from, intolerant to, or ineligible for (due to unavailability or contraindication) local standard of care therapies and have one of the following locally advanced or metastatic tumor types: * Head and Neck Squamous Cell Carcinoma (HNSCC) * Gastric/GEJ Cancer * Biliary Tract Cancer (BTC) * Esophageal Squamous Cell Carcinoma (ESCC) * Ovarian Cancer * Endometrial Carcinoma * Cervical Cancer * Non-Small Cell Lung Cancer (NSCLC) Exclusion Criteria: * Has malignancies other than disease under study within the past 3 years * Has not adequately recovered from recent major surgery * Has ongoing clinically significant toxicity related to prior therapy * Has known sensitivity to any component of CR-002 * Has received prior treatment with an antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload. * Has active central nervous system (CNS) metastases * Has a medical or psychological condition that could interfere with study participation, increase risk, or affect interpretation of the study results * NOTE: Other protocol defined Inclusion and Exclusion criteria may apply.